MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs

Mikio Kakumoto, Kohji Takara, Toshiyuki Sakaeda, Yusuke Tanigawara, Tomoko Kita, Katsuhiko Okumura

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The multidrug transporter, MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs was examined in vitro by using the MDR1-overexpressing LLC-GA5-COL150 cells, which were established by transfection with human MDR1 cDNA into porcine kidney epithelial LLC-PK1 cells. Amiodarone, its active metabolite monodesethyl-amiodarone (DEA), and quinidine markedly inhibited the basal-to-apical transport (renal secretion) of [ 3H]digoxin and increased the apical-to-basal transport (reabsorption), but cibenzoline and lidocaine showed slight inhibition of the transport, and disopyramide and mexiletin had no such effects. The IC 50 values for amiodarone, DEA and quinidine on [3H]digoxin transport in LLC-GA5-COL150 cells were 5.48 μM, 1.27 μM and 9.52 μM, respectively. These were comparable to, or only several times the achievable concentration in clinical use, suggesting that MDR1 could be responsible for the drug interaction between digoxin and amiodarone found in clinical reports and that DEA contributes the elevation of digoxin serum concentration. Similarly, dipyridamole altered the transport, but isosorbide showed only slight modification of the transport. The IC50 value for dipyridamole was 40.0 μM, also only several times the achievable concentration in clinical use, indicating a risk of interaction.

Original languageEnglish
Pages (from-to)1604-1607
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Volume25
Issue number12
DOIs
Publication statusPublished - 2002 Dec

Fingerprint

Digoxin
Amiodarone
Quinidine
Pharmaceutical Preparations
Dipyridamole
Isosorbide
LLC-PK1 Cells
Disopyramide
Kidney
Lidocaine
Drug Interactions
Inhibitory Concentration 50
Transfection
Swine
Complementary DNA
Epithelial Cells
Serum

Keywords

  • Antianginal drug
  • Antiarrythmic drug
  • Digoxin
  • Drug interaction
  • MDR1, P-glycoprotein

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. / Kakumoto, Mikio; Takara, Kohji; Sakaeda, Toshiyuki; Tanigawara, Yusuke; Kita, Tomoko; Okumura, Katsuhiko.

In: Biological and Pharmaceutical Bulletin, Vol. 25, No. 12, 12.2002, p. 1604-1607.

Research output: Contribution to journalArticle

Kakumoto, Mikio ; Takara, Kohji ; Sakaeda, Toshiyuki ; Tanigawara, Yusuke ; Kita, Tomoko ; Okumura, Katsuhiko. / MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. In: Biological and Pharmaceutical Bulletin. 2002 ; Vol. 25, No. 12. pp. 1604-1607.
@article{72065f61724c42d3aec490204e15972c,
title = "MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs",
abstract = "The multidrug transporter, MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs was examined in vitro by using the MDR1-overexpressing LLC-GA5-COL150 cells, which were established by transfection with human MDR1 cDNA into porcine kidney epithelial LLC-PK1 cells. Amiodarone, its active metabolite monodesethyl-amiodarone (DEA), and quinidine markedly inhibited the basal-to-apical transport (renal secretion) of [ 3H]digoxin and increased the apical-to-basal transport (reabsorption), but cibenzoline and lidocaine showed slight inhibition of the transport, and disopyramide and mexiletin had no such effects. The IC 50 values for amiodarone, DEA and quinidine on [3H]digoxin transport in LLC-GA5-COL150 cells were 5.48 μM, 1.27 μM and 9.52 μM, respectively. These were comparable to, or only several times the achievable concentration in clinical use, suggesting that MDR1 could be responsible for the drug interaction between digoxin and amiodarone found in clinical reports and that DEA contributes the elevation of digoxin serum concentration. Similarly, dipyridamole altered the transport, but isosorbide showed only slight modification of the transport. The IC50 value for dipyridamole was 40.0 μM, also only several times the achievable concentration in clinical use, indicating a risk of interaction.",
keywords = "Antianginal drug, Antiarrythmic drug, Digoxin, Drug interaction, MDR1, P-glycoprotein",
author = "Mikio Kakumoto and Kohji Takara and Toshiyuki Sakaeda and Yusuke Tanigawara and Tomoko Kita and Katsuhiko Okumura",
year = "2002",
month = "12",
doi = "10.1248/bpb.25.1604",
language = "English",
volume = "25",
pages = "1604--1607",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "12",

}

TY - JOUR

T1 - MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs

AU - Kakumoto, Mikio

AU - Takara, Kohji

AU - Sakaeda, Toshiyuki

AU - Tanigawara, Yusuke

AU - Kita, Tomoko

AU - Okumura, Katsuhiko

PY - 2002/12

Y1 - 2002/12

N2 - The multidrug transporter, MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs was examined in vitro by using the MDR1-overexpressing LLC-GA5-COL150 cells, which were established by transfection with human MDR1 cDNA into porcine kidney epithelial LLC-PK1 cells. Amiodarone, its active metabolite monodesethyl-amiodarone (DEA), and quinidine markedly inhibited the basal-to-apical transport (renal secretion) of [ 3H]digoxin and increased the apical-to-basal transport (reabsorption), but cibenzoline and lidocaine showed slight inhibition of the transport, and disopyramide and mexiletin had no such effects. The IC 50 values for amiodarone, DEA and quinidine on [3H]digoxin transport in LLC-GA5-COL150 cells were 5.48 μM, 1.27 μM and 9.52 μM, respectively. These were comparable to, or only several times the achievable concentration in clinical use, suggesting that MDR1 could be responsible for the drug interaction between digoxin and amiodarone found in clinical reports and that DEA contributes the elevation of digoxin serum concentration. Similarly, dipyridamole altered the transport, but isosorbide showed only slight modification of the transport. The IC50 value for dipyridamole was 40.0 μM, also only several times the achievable concentration in clinical use, indicating a risk of interaction.

AB - The multidrug transporter, MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs was examined in vitro by using the MDR1-overexpressing LLC-GA5-COL150 cells, which were established by transfection with human MDR1 cDNA into porcine kidney epithelial LLC-PK1 cells. Amiodarone, its active metabolite monodesethyl-amiodarone (DEA), and quinidine markedly inhibited the basal-to-apical transport (renal secretion) of [ 3H]digoxin and increased the apical-to-basal transport (reabsorption), but cibenzoline and lidocaine showed slight inhibition of the transport, and disopyramide and mexiletin had no such effects. The IC 50 values for amiodarone, DEA and quinidine on [3H]digoxin transport in LLC-GA5-COL150 cells were 5.48 μM, 1.27 μM and 9.52 μM, respectively. These were comparable to, or only several times the achievable concentration in clinical use, suggesting that MDR1 could be responsible for the drug interaction between digoxin and amiodarone found in clinical reports and that DEA contributes the elevation of digoxin serum concentration. Similarly, dipyridamole altered the transport, but isosorbide showed only slight modification of the transport. The IC50 value for dipyridamole was 40.0 μM, also only several times the achievable concentration in clinical use, indicating a risk of interaction.

KW - Antianginal drug

KW - Antiarrythmic drug

KW - Digoxin

KW - Drug interaction

KW - MDR1, P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=0042037275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042037275&partnerID=8YFLogxK

U2 - 10.1248/bpb.25.1604

DO - 10.1248/bpb.25.1604

M3 - Article

C2 - 12499648

AN - SCOPUS:0042037275

VL - 25

SP - 1604

EP - 1607

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 12

ER -